201 related articles for article (PubMed ID: 29726727)
1. Epigenetic therapy and dermatologic disease: moving beyond CTCL.
Mervis JS; McGee JS
J Dermatolog Treat; 2019 Feb; 30(1):68-73. PubMed ID: 29726727
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation and inflammatory skin diseases.
Mervis JS; McGee JS
Arch Dermatol Res; 2020 Sep; 312(7):461-466. PubMed ID: 31696298
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Lai P; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):34-51. PubMed ID: 33628583
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy in hematological cancers.
Dimopoulos K; Grønbaek K
APMIS; 2019 May; 127(5):316-328. PubMed ID: 30859683
[TBL] [Abstract][Full Text] [Related]
6. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
7. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
Lopez AT; Bates S; Geskin L
Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
9. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
[TBL] [Abstract][Full Text] [Related]
10. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
11. Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.
Qu K; Zaba LC; Satpathy AT; Giresi PG; Li R; Jin Y; Armstrong R; Jin C; Schmitt N; Rahbar Z; Ueno H; Greenleaf WJ; Kim YH; Chang HY
Cancer Cell; 2017 Jul; 32(1):27-41.e4. PubMed ID: 28625481
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
13. Non-coding RNAs in the epigenetic landscape of cutaneous T-cell lymphoma.
Adeeb M; Therachiyil L; Moton S; Buddenkotte J; Alam MA; Uddin S; Steinhoff M; Ahmad A
Int Rev Cell Mol Biol; 2023; 380():149-171. PubMed ID: 37657857
[TBL] [Abstract][Full Text] [Related]
14. Epigenetics of Breast Cancer: Clinical Status of Epi-drugs and Phytochemicals.
Shukla S; Penta D; Mondal P; Meeran SM
Adv Exp Med Biol; 2019; 1152():293-310. PubMed ID: 31456191
[TBL] [Abstract][Full Text] [Related]
15. Melanoma epigenetics: novel mechanisms, markers, and medicines.
Lee JJ; Murphy GF; Lian CG
Lab Invest; 2014 Aug; 94(8):822-38. PubMed ID: 24978641
[TBL] [Abstract][Full Text] [Related]
16. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation and cancer (review).
Chen QW; Zhu XY; Li YY; Meng ZQ
Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
[TBL] [Abstract][Full Text] [Related]
18. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
Mishra A; La Perle K; Kwiatkowski S; Sullivan LA; Sams GH; Johns J; Curphey DP; Wen J; McConnell K; Qi J; Wong H; Russo G; Zhang J; Marcucci G; Bradner JE; Porcu P; Caligiuri MA
Cancer Discov; 2016 Sep; 6(9):986-1005. PubMed ID: 27422033
[TBL] [Abstract][Full Text] [Related]
19. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
Rondelet G; Wouters J
Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
[TBL] [Abstract][Full Text] [Related]
20. Methylation patterns of cutaneous T-cell lymphomas.
Iżykowska K
Exp Dermatol; 2021 Aug; 30(8):1135-1140. PubMed ID: 32350933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
